- Home
- MMU vs CVAC Comparison
MMU vs CVAC Comparison
Compare MMU & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMU
- CVAC
- Stock Information
- Founded
- MMU 1992
- CVAC 2000
- Country
- MMU United States
- CVAC Germany
- Employees
- MMU N/A
- CVAC N/A
- Industry
- MMU Investment Managers
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- MMU Finance
- CVAC Health Care
- Exchange
- MMU Nasdaq
- CVAC Nasdaq
- Market Cap
- MMU 562.0M
- CVAC 643.8M
- IPO Year
- MMU N/A
- CVAC 2020
- Fundamental
- Price
- MMU $10.43
- CVAC $2.83
- Analyst Decision
- MMU
- CVAC Hold
- Analyst Count
- MMU 0
- CVAC 3
- Target Price
- MMU N/A
- CVAC $10.00
- AVG Volume (30 Days)
- MMU 170.7K
- CVAC 387.0K
- Earning Date
- MMU 01-01-0001
- CVAC 11-12-2024
- Dividend Yield
- MMU 4.92%
- CVAC N/A
- EPS Growth
- MMU N/A
- CVAC N/A
- EPS
- MMU N/A
- CVAC N/A
- Revenue
- MMU N/A
- CVAC $70,565,734.00
- Revenue This Year
- MMU N/A
- CVAC $123.97
- Revenue Next Year
- MMU N/A
- CVAC N/A
- P/E Ratio
- MMU N/A
- CVAC N/A
- Revenue Growth
- MMU N/A
- CVAC 75.11
- 52 Week Low
- MMU $8.60
- CVAC $2.22
- 52 Week High
- MMU $10.45
- CVAC $6.30
- Technical
- Relative Strength Index (RSI)
- MMU 41.20
- CVAC 48.05
- Support Level
- MMU $10.36
- CVAC $2.63
- Resistance Level
- MMU $10.46
- CVAC $2.95
- Average True Range (ATR)
- MMU 0.11
- CVAC 0.15
- MACD
- MMU -0.00
- CVAC 0.02
- Stochastic Oscillator
- MMU 34.92
- CVAC 50.62
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. It predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations). Under normal market conditions, a majority of its total assets are invested in municipal obligations rated investment grade at the time of investment.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.